Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Market access of gene therapies across Europe, USA, and Canada: challenges, trends, and solutions
Eline van Overbeeke, Sissel Michelsen, Mondher Toumi, et al.
Drug Discovery Today (2020) Vol. 26, Iss. 2, pp. 399-415
Open Access | Times Cited: 34

Showing 1-25 of 34 citing articles:

Management of Immune-Related Adverse Events in Patients Treated With Chimeric Antigen Receptor T-Cell Therapy: ASCO Guideline
Bianca Santomasso, Loretta J. Nastoupil, Sherry Adkins, et al.
Journal of Clinical Oncology (2021) Vol. 39, Iss. 35, pp. 3978-3992
Open Access | Times Cited: 118
Advanced gene nanocarriers/scaffolds in nonviral-mediated delivery system for tissue regeneration and repair
Wanheng Zhang, Yan Hou, Shiyi Yin, et al.
Journal of Nanobiotechnology (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 16
Challenges and solutions to the sustainability of gene and cell therapies
Celeste Scotti, Alessandro Aiuti, Luigi Naldini
Nature Reviews Genetics (2025)
Closed Access | Times Cited: 1
How are health technology assessment bodies responding to the assessment challenges posed by cell and gene therapy?
Michael Drummond, Oriana Ciani, Giulia Fornaro, et al.
BMC Health Services Research (2023) Vol. 23, Iss. 1
Open Access | Times Cited: 19
Confronting High Costs And Clinical Uncertainty: Innovative Payment Models For Gene Therapies
Caroline Horrow, Aaron S. Kesselheim
Health Affairs (2023) Vol. 42, Iss. 11, pp. 1532-1540
Closed Access | Times Cited: 14
Gene Therapy in Hemophilia A: Achievements, Challenges, and Perspectives
Natasha S. Bala, Courtney D. Thornburg
Seminars in Thrombosis and Hemostasis (2024)
Closed Access | Times Cited: 5
Individualized therapy trials: navigating patient care, research goals and ethics
Patrick Bodilly Kane, Merlin Bittlinger, Jonathan Kimmelman
Nature Medicine (2021) Vol. 27, Iss. 10, pp. 1679-1686
Closed Access | Times Cited: 29
Analysis of drug pricing drivers under South Korea’s pharmaco-economic evaluation exemption policy (2015–2022)
Jong Hyuk Lee, Jong Hyuk Lee
Frontiers in Pharmacology (2025) Vol. 15
Open Access
Gene Therapy: An Historical Overview for Familial Hearing Loss
O’neil W. Guthrie
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 4, pp. 1469-1469
Open Access
Beyond Reimbursement Status: Availability of Advanced Therapy Medicinal Products Across the European Union
Zora Čechová, Jana Kubátová, A Bártová, et al.
Therapeutic Innovation & Regulatory Science (2025)
Open Access
Patient preferences for gene therapy in haemophilia: Results from the PAVING threshold technique survey
Eline van Overbeeke, Brett Hauber, Sissel Michelsen, et al.
Haemophilia (2021) Vol. 27, Iss. 6, pp. 957-966
Open Access | Times Cited: 21
Cell and gene therapy regulatory, pricing, and reimbursement framework: With a focus on South Korea and the EU
Sungkyung Lee, Jong Hyuk Lee
Frontiers in Public Health (2023) Vol. 11
Open Access | Times Cited: 9
Analysis of the Gene Therapies Authorized by the United States Food and Drug Administration and the European Medicines Agency
Buthainah Ghanem, Enrique Seoane‐Vazquez, Lawrence M. Brown, et al.
Medical Care (2023) Vol. 61, Iss. 7, pp. 438-447
Closed Access | Times Cited: 8
A Systematic Review of Challenges and Opportunities in the Implementation of Managed Entry Agreements for Advanced Therapy Medicinal Products
Andrea Greco, Geert Frederix, Lotty Hooft, et al.
Clinical Therapeutics (2024)
Open Access | Times Cited: 3
How to balance valuable innovation with affordable access to medicines in Belgium?
Steven Simoens, Khadidja Abdallah, Liese Barbier, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 14
Gene Therapy and Hemophilia: Where Do We Go from Here?
Nancy S. Bolous, Nidhi Bhatt, Nickhill Bhakta, et al.
Journal of Blood Medicine (2022) Vol. Volume 13, pp. 559-580
Open Access | Times Cited: 14
Critical Reflections on Reimbursement and Access of Advanced Therapies
Steven Simoens, Katrien De Groote, Cornelis Boersma
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 13
Cross-Sectional Analysis of Exome Sequencing Diagnosis in Patients With Neurologic Phenotypes Facing Barriers to Clinical Testing
Sonya Watson, Kathie J. Ngo, Hannah A. Stevens, et al.
Neurology Genetics (2024) Vol. 10, Iss. 3
Open Access | Times Cited: 2
Gene Therapy for Neuromuscular Diseases: Health Economic Challenges and Future Perspectives
Erik Landfeldt
Journal of Neuromuscular Diseases (2022) Vol. 9, Iss. 6, pp. 675-688
Open Access | Times Cited: 10
Challenges for gene therapy in the financial sustainability of health systems: a scoping review
Hugo Ossandon, Nicolás Armijo, Constanza Vargas, et al.
Orphanet Journal of Rare Diseases (2024) Vol. 19, Iss. 1
Open Access | Times Cited: 1
Managed Entry Agreements for High-Cost, One-Off Potentially Curative Therapies: A Framework and Calculation Tool to Determine Their Suitability
Marcelien Callenbach, Rick A. Vreman, Christine Leopold, et al.
PharmacoEconomics (2024)
Open Access | Times Cited: 1
Patient Preferences to Assess Value IN Gene Therapies: Protocol Development for the PAVING Study in Hemophilia
Eline van Overbeeke, Brett Hauber, Sissel Michelsen, et al.
Frontiers in Medicine (2021) Vol. 8
Open Access | Times Cited: 9
Surrogacy and the Valuation of ATMPs: Taking Our Place in the Evidence Generation/Assessment Continuum
D. Gladwell, Oriana Ciani, Adam Parnaby, et al.
PharmacoEconomics (2023) Vol. 42, Iss. 2, pp. 137-144
Closed Access | Times Cited: 2
The Increasing Investment of Real Estate in the Health System—A Comparison between the USA and Europe
Marta Bachmann, Stephanie Taha‐Mehlitz, Vincent Ochs, et al.
Healthcare (2021) Vol. 9, Iss. 12, pp. 1633-1633
Open Access | Times Cited: 4
Medicaid best price reforms to enable innovative payment models for cell and gene therapies
Casey Quinn, Michael Ciarametaro, Brian Sils, et al.
Expert Review of Pharmacoeconomics & Outcomes Research (2022) Vol. 23, Iss. 2, pp. 191-203
Open Access | Times Cited: 3
Page 1 - Next Page

Scroll to top